1. Antihyperglycemic Therapy

3. The Link Between Diabetes and CVD

4. DPP-4 Inhibitors Demonstrated CV Safety

5. SAVOR-TIMI 53, EXAMINE, and TECOS First Hospitalization for Heart Failure

6. Heart Failure in the SAVOR-TIMI 53 Trial

7. Saxagliptin and Alogliptin Risk for Heart Failure

8. ELIXA: Lixisenatide

9. LEADER: Liraglutide

10. SUSTAIN-6: Semaglutide*

11. Making Sense of the CVOT Data

12. DPP-4 Inhibitors and GLP-1 Receptor Agonists for T2D

13. Clinical Applicability of CVOT Data

14. Renal Glucose Handling

15. EMPA-REG OUTCOME: Empagliflozin Cardiovascular Outcomes and Death From Any Cause

16. Empagliflozin New FDA Indication and Patient Education

17. IRIS: Pioglitazone

18. Metformin As First-Line Therapy in Patients With T2D

19. Patient Case Study

20. 2016 ESC Heart Failure Guidelines and ADA 2017 Update

21. Cardiologists and Endocrinologists Working Together to Lower HbA1c

22. Trends in Diabetes-Related Complications Among Adults With Diabetes, 1990-2010

23. Proposed Pleiotropic CV Effects of SGLT-2 Inhibitors

24. Proposed Pleiotropic CV Effects of GLP-1 Receptor Agonists

25. Closing Comments

26. Abbreviations

27. Abbreviations (cont)